{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T07:47:43Z","timestamp":1793346463773,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Germany","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jacl.2026.02.003","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T16:33:10Z","timestamp":1770395590000},"page":"770-777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Beyond lipid lowering: Effects of PCSK9 inhibition on inflammation and HDL function"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0029-8663","authenticated-orcid":false,"given":"Maximilian","family":"Seidel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix S.","family":"Seibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Doevelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Rohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Bertram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas F.","family":"Kolodziej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Pagonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4898-0389","authenticated-orcid":false,"given":"Johannes","family":"Korth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Babel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timm H.","family":"Westhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jacl.2026.02.003_bib1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2174\/092986707779313381","article-title":"Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins","volume":"14","author":"Lahera","year":"2007","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jacl.2026.02.003_bib2","article-title":"Statins and oxidative stress in the cardiovascular system","author":"Margariti","year":"2017","journal-title":"Curr Pharm Des"},{"issue":"22","key":"10.1016\/j.jacl.2026.02.003_bib3","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.2174\/1568026614666141203130324","article-title":"Pleiotropic effects of statins in atherosclerotic disease: focus on the antioxidant activity of atorvastatin","volume":"14","author":"Profumo","year":"2014","journal-title":"Curr Top Med Chem"},{"issue":"4","key":"10.1016\/j.jacl.2026.02.003_bib4","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S0008-6363(00)00146-2","article-title":"Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability","volume":"47","author":"Koh","year":"2000","journal-title":"Cardiovasc Res"},{"issue":"2","key":"10.1016\/j.jacl.2026.02.003_bib5","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.atherosclerosis.2008.08.022","article-title":"The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis","volume":"203","author":"Blum","year":"2009","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.jacl.2026.02.003_bib6","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13534","article-title":"The role of statins in the differentiation and function of bone cells","volume":"51","author":"Chamani","year":"2021","journal-title":"Eur J Clin Invest"},{"issue":"12","key":"10.1016\/j.jacl.2026.02.003_bib7","doi-asserted-by":"crossref","first-page":"41F","DOI":"10.1016\/j.amjcard.2008.04.018","article-title":"Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker","volume":"101","author":"Corson","year":"2008","journal-title":"Am\u00a0J\u00a0Cardiol"},{"key":"10.1016\/j.jacl.2026.02.003_bib8","doi-asserted-by":"crossref","DOI":"10.1177\/2058738419827154","article-title":"Lp-PLA2, a new biomarker of vascular disorders in metabolic diseases","volume":"33","author":"De Stefano","year":"2019","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"1","key":"10.1016\/j.jacl.2026.02.003_bib9","first-page":"79","article-title":"Lipoprotein-associated phospholipase A2: the story continues","volume":"40","author":"Huang","year":"2019","journal-title":"Med\u00a0Res\u00a0Rev"},{"issue":"1","key":"10.1016\/j.jacl.2026.02.003_bib10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.atherosclerosis.2005.05.006","article-title":"The effect of statin therapy on lipoprotein associated phospholipase A2 levels","volume":"182","author":"Albert","year":"2005","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.jacl.2026.02.003_bib11","first-page":"1417","article-title":"Effect of statin treatment on lipoprotein-associated phospholipase A2 mass and activity: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"39","author":"Sahebkar","year":"2025","journal-title":"Cardiovasc\u00a0Drugs\u00a0Ther"},{"issue":"3","key":"10.1016\/j.jacl.2026.02.003_bib12","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/cvr\/cvu147","article-title":"HDL-mediated mechanisms of protection in cardiovascular disease","volume":"103","author":"Kontush","year":"2014","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacl.2026.02.003_bib13","article-title":"Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation","volume":"9","author":"Palumbo","year":"2022","journal-title":"Front\u00a0Mol\u00a0Biosci"},{"issue":"6","key":"10.1016\/j.jacl.2026.02.003_bib14","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.187889","article-title":"Reduced high-density lipoprotein antioxidant function in patients with coronary artery disease and acute coronary syndrome","volume":"10","author":"Sasko","year":"2025","journal-title":"JCI Insight"},{"issue":"128","key":"10.1016\/j.jacl.2026.02.003_bib15","doi-asserted-by":"crossref","DOI":"10.3791\/56325","article-title":"Cell-free biochemical fluorometric enzymatic assay for high-throughput measurement of lipid peroxidation in high density lipoprotein","author":"Sen Roy","year":"2017","journal-title":"J Vis Exp"},{"issue":"11","key":"10.1016\/j.jacl.2026.02.003_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111716","article-title":"A high throughput biochemical fluorometric method for measuring lipid peroxidation in HDL","volume":"9","author":"Kelesidis","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jacl.2026.02.003_bib17","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3389\/fphys.2019.00402","article-title":"Repeated changes to the gravitational field negatively affect the serum concentration of select growth factors and cytokines","volume":"10","author":"Stervbo","year":"2019","journal-title":"Front Physiol"},{"issue":"13","key":"10.1016\/j.jacl.2026.02.003_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12134458","article-title":"Empagliflozin reduces interleukin-6 levels in patients with heart failure","volume":"12","author":"Gotzmann","year":"2023","journal-title":"J Clin Med"},{"issue":"22","key":"10.1016\/j.jacl.2026.02.003_bib19","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jacl.2026.02.003_bib20","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jacl.2026.02.003_bib21","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jacl.2026.02.003_bib22","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/01.CIR.0000116763.91992.F1","article-title":"Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study","volume":"109","author":"Ballantyne","year":"2004","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jacl.2026.02.003_bib23","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.atherosclerosis.2007.12.001","article-title":"Lp-PLA2 activity and mass are associated with increased incidence of ischemic stroke: a population-based cohort study from Malm\u00f6, Sweden","volume":"200","author":"M","year":"2008","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.jacl.2026.02.003_bib24","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1161\/ATVBAHA.115.306647","article-title":"Lipoprotein-associated phospholipase A2 and incident peripheral arterial disease in older adults: the cardiovascular health study","volume":"36","author":"Garg","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.jacl.2026.02.003_bib25","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1373\/clinchem.2007.093468","article-title":"Variability of serial lipoprotein-associated phospholipase A2 measurements in post myocardial infarction patients: results from the AIRGENE Study Center Augsburg","volume":"54","author":"Khuseyinova","year":"2008","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2026.02.003_bib26","doi-asserted-by":"crossref","DOI":"10.1177\/10760296251360015","article-title":"The value of Lp-PLA2 as a biomarker for the diagnosis of plaque stability in atherosclerosis: a meta-analysis","volume":"31","author":"Huang","year":"2025","journal-title":"Clin Appl Thromb Hemost"},{"issue":"1","key":"10.1016\/j.jacl.2026.02.003_bib27","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/1744666X.2022.2017281","article-title":"The role of PCSK9 in inflammation, immunity, and autoimmune diseases","volume":"18","author":"Frostegard","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jacl.2026.02.003_bib28","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/4396368","article-title":"The CXCL10\/CXCR3 axis and cardiac inflammation: implications for immunotherapy to treat infectious and noninfectious diseases of the heart","volume":"2016","author":"Altara","year":"2016","journal-title":"J Immunol Res"},{"issue":"526","key":"10.1016\/j.jacl.2026.02.003_bib29","article-title":"Interleukin-2 shapes the cytotoxic T cell proteome and immune environment-sensing programs","volume":"11","author":"Rollings","year":"2018","journal-title":"Sci\u00a0Signal"},{"issue":"1","key":"10.1016\/j.jacl.2026.02.003_bib30","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1038\/s41598-018-20425-x","article-title":"PCSK9 induces a pro-inflammatory response in macrophages","volume":"8","author":"Ricci","year":"2018","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.jacl.2026.02.003_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.870","article-title":"PCSK9 promotes T helper 1 and T helper 17 cell differentiation by activating the nuclear factor-kappaB pathway in ankylosing spondylitis","volume":"11","author":"Cai","year":"2023","journal-title":"Immun Inflamm Dis"},{"issue":"4","key":"10.1016\/j.jacl.2026.02.003_bib32","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/ehjcvp\/pvz022","article-title":"PCSK9 and inflammation: a review of experimental and clinical evidence","volume":"5","author":"Momtazi-Borojeni","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"3","key":"10.1016\/j.jacl.2026.02.003_bib33","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1042\/bj2650621","article-title":"Interleukin-6 and the acute phase response","volume":"265","author":"Heinrich","year":"1990","journal-title":"Biochem J"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426000267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426000267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:05:36Z","timestamp":1777622736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426000267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1933287426000267"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.02.003","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond lipid lowering: Effects of PCSK9 inhibition on inflammation and HDL function","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}